Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Drexler

Anesthesiology Mount Kisco, NY Medical Doctor

NPI 1427051309 CMS profile 517615

400 E Main St, Northern Westchester Hospital, Mount Kisco, NY 10549

Open in the dashboard

General payments

$7,594

318 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Drexler of Mount Kisco, NY is reported in the CMS Open Payments database as having received $7,594 across 318 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,597 67
2024 General $3,310 96
2023 General $1,488 92
2022 General $577 27
2021 General $428 30
2020 General $82 5
2019 General $112 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Drexler
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Steven Drexler were reported at $1,597. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Steven Drexler Anesthesiology median Middle half National median
2019 $112 $72 $23–$151 $163
2020 $82 $36 $17–$120 $114
2021 $428 $49 $21–$135 $132
2022 $577 $52 $22–$144 $149
2023 $1,488 $53 $23–$143 $160
2024 $3,310 $55 $25–$150 $164
2025 $1,597 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Djo, LLC $1,672 1 payment
  2. Takeda Pharmaceuticals U.S.A., Inc. $1,294 73 payments
  3. Janssen Biotech, Inc. $776 26 payments
  4. Celgene Corporation $633 73 payments
  5. AbbVie, Inc. $596 16 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $523 36 payments
  7. QOL Medical, LLC $517 34 payments
  8. Lilly USA, LLC $305 17 payments
  9. Intercept Pharmaceuticals, Inc. $189 10 payments
  10. Regeneron Healthcare Solutions, Inc. $176 9 payments
  11. Other $913 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,921 317 payments
  2. Debt forgiveness $1,672 1 payment
Products named General payments · program years 2019–2025
  1. ENTYVIO $1,093 64 payments
  2. ZEPOSIA $599 70 payments
  3. STELARA $575 21 payments
  4. Sucraid $465 31 payments
  5. TREMFYA $443 16 payments
  6. XIFAXAN $412 28 payments
  7. SIMPONI ARIA $331 15 payments
  8. SIMPONI $331 15 payments
  9. OMVOH $297 16 payments
  10. SKYRIZI $291 5 payments
  11. Other $2,037 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$31,128

Medicare's payments for the services billed

Medicare patients

283

Average age 73

Services billed

287

178 women, 105 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 42%
Diabetes 23%
Osteoporosis 21%
Ischemic heart disease 20%
Cancer 16%
Depression 14%
COPD 11%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $435
$435 — —
ZEPOSIA
  • Celgene Corporation $196
$196 — —
OMVOH
  • Lilly USA, LLC $151
$151 — —
SKYRIZI
  • AbbVie, Inc. $141
$141 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $125
$125 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

318 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record